Estrella Immunopharma, Inc.

Estrella Immunopharma, Inc., trading under the ticker ESLA, is a clinical-stage biopharmaceutical company focused on immunotherapy that reached public markets through a SPAC merger. The company filed an 8-K current report with the SEC on September 20, 2023, accession number 0001213900-23-077995, reflecting ongoing disclosure obligations following its SPAC-related listing. Operating in the healthcare and biotechnology sector, Estrella Immunopharma represents the wave of life-sciences SPACs that gained momentum in the early 2020s as blank-check vehicles targeted drug development and immunology platforms. Investors and analysts tracking SPAC-backed biotech companies can find the full filing history, sponsor details, and deal timeline for ESLA by signing up for complete data access at SpacDesk.